Abstract
In patients presenting with symptoms centered in the upper abdomen, functional dyspepsia (FD) is the most frequent diagnosis after exclusion of specific organic diseases by adequate diagnosis including endoscopy. FD is included in the overall clinical picture of functional gastrointestinal disease and is associated with one-third or more of patients with irritable bowel syndrome. The new Rome IV criteria propose two distinct entities of FD: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) according to predominant symptom grouping. In addition, the two entities frequently overlap with other functional gastrointestinal diseases. Important progress has been made in our understanding of underlying etiologies and mechanisms in FD. They include-beyond established disorders in gastroduodenal motility and visceral sensitivity-environmental and dietary factors, exposure to infectious and noninfectious inflammatory reactions, and to a minor extent also genetic factors. An essential aspect addresses the brain-gut axis and a new dimension is introduced by its interaction with the gastrointestinal microbiome. These advances will need to be taken into account in our diagnostic approach in the search for distinct structural and biochemical abnormalities that are not considered in routine clinical practice yet. Our advanced understanding of mechanisms will also be reflected by future developments of new targeted medications. Recommendations for lifestyle, nutrition, and medications including acid inhibitors, prokinetics, phytopharmaceuticals, antidepressants, and empirically microbiota modulators for the treatment of FD are currently available.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 1861-9681 |
Sprache: | Deutsch |
Dokumenten ID: | 65727 |
Datum der Veröffentlichung auf Open Access LMU: | 19. Jul. 2019, 12:18 |
Letzte Änderungen: | 04. Nov. 2020, 13:46 |